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Background: Multimetal organic frameworks (M-MOFs) were synthesized by including a 
second metal ion with the main base metal in the synthesis process to enhance their applications 
for drug delivery. Aceclofenac (ACF), a nonsteroidal anti-inflammatory analgesic drug of low 
aqueous solubility, was selected as a candidate for the drug delivery system
Purpose: This study aimed to evaluate the loading capacity (LC) and entrapment efficiency (EE) 
percentages of multi-Material of Institute Lavoisier (MIL)-100(Fe) (M-MIL-100(Fe)) for ACF.
Materials and methods: Hydrothermal synthesis procedure was used to prepare multi-MIL-
100(Fe) samples (Zn I-MIL-100(Fe), Zn II-MIL-100(Fe), Ca I-MIL-100(Fe), Ca II-MIL-100-
(Fe), Mg I-MIL-100(Fe), Mg II-MIL-100(Fe), Mn I-MIL-100(Fe), and Mn II-MIL-100(Fe)). 
The characterization of M-MIL-100(Fe) samples was evaluated by X-ray powder diffraction 
(XRD), Fourier transform infrared spectra, scanning electron microscope (SEM), TGA, and N
2
 
adsorption isotherms. The LC of M-MIL-100(Fe) and EE of ACF were determined. Nuclear 
magnetic resonance (NMR) and zeta-potential analyses were employed to confirm qualitatively 
the drug loading within M-MIL-100(Fe).
Results: The ACF LC of MIL-100(Fe) was 27%, whereas the LC of M-MIL-100(Fe) was signifi-
cantly increased and ranged from 37% in Ca I-MIL-100(Fe) to about 57% and 59% in Mn II-MIL-
100(Fe) and Zn II-MIL-100(Fe), respectively. The ACF@M-MOFs release profiles showed slow 
release rates in phosphate buffer solutions at pH 6.8 and 7.4 as compared to the ACF@MIL-100(Fe).
Conclusion: Therefore, M-MOFs showed a significant potential as a carrier for drug delivery 
systems.
Keywords: aceclofenac, Mixed metal-MOF, MIL-100, drug delivery, drug loading
Introduction
The use of distinct molecular units in the assembly of extended networks has importance 
in porous metal organic framework (MOF) materials because they have large sur-
face areas, tunable pore sizes, and pore volumes.1 Nowadays, gas storage and drug 
delivery systems are among the most identified applications of MOFs in the industrial 
and research fields.2–4 MOFs have been employed as drug carriers for more than a 
decade owing to their advantageous properties.5 Currently, the most biocompatible 
metal is iron, which has been employed in the synthesis of different types of MOFs 
such as MIL100(Fe).4,6 Employing a pure organic linker or one metal in constructing 
traditional MOFs is regarded as immobilizing functional sites. However, mixed or 
multi-MOFs (M-MOFs) are utilized to coordinate further metal ions, which can gen-
erate improvement in the pore size and surface area of such materials. This can also 
immobilize different metal sites such as catalytically active sites or open metal sites 
for their functional properties.4,5
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M-MOFs are usually synthesized by adding further metals 
in the main structure by a direct synthesis or postsynthesis 
procedures.7 The direct synthesis strategy can be achieved by 
replacing one organic linker by a corresponding derivative8 
or by employing two different metals that have the same 
Coulombic charge, ionic radius, and behavior in order to 
increase the chances of having simultaneous and homoge-
neous co-incorporation of the two metals.9 The postsynthesis 
strategy is based on the partial replacement of the metal or 
partial replacement of the linker.10
These materials have demonstrated a high drug loading 
and controlled release of loaded drugs.11 A well-regulated 
drug delivery system is important to diminish side effects 
and improve the therapeutic efficacy of drugs. Furthermore, 
researchers have made significant improvement in the field 
of drug delivery by MOFs, owing to their simplistic synthesis 
on a nanoscale and different functional group insertion and 
surface chemistry.12 Drug loading can be achieved by three 
strategies according to the location of the pay–load and pay–
load–carrier interactions: an encapsulation strategy, direct 
assembly strategy, and postsynthesis strategy.13 Sun et al have 
proven that mixed ligand MOFs-2 showed the best perfor-
mance in transporting doxorubicin drug as the consequence 
of highest loading efficiency even at 48 hours.47
Aceclofenac (ACF) is classified as nonsteroidal anti-
inflammatory drug, as shown in Figure 1. It has poor water 
solubility (0.058 µg/mL)14 and high permeability, which is 
regarded as class II according to the biopharmaceutics clas-
sification system.15 It is widely used to relieve pain and reduce 
inflammation. The major obstacle for its optimum bioavail-
ability is its intrinsic properties such as poor solubility16 and 
kinetic release profile. Different drug delivery systems have 
been employed to improve ACF bioavailability, enhance 
its therapeutic efficacy, and prolong its release.17–20 The 
drug-loading and drug-release processes are mainly ruled 
by structural parameters of carriers and drug as well as their 
hydrophobic and hydrophilic properties.21
Controlled drug release systems with appropriate carriers, 
which include liposomes, dendrimers, micro sponges, 
microparticles, and micelles, have been employed to increase 
the therapeutic effectiveness and minimize the side effects of 
low water-soluble drugs. Several undesired adverse effects, 
which are accompanied with ACF oral administration, such 
as gastrointestinal tract (GIT) irritation, ulceration, and 
bleeding,22 are leading the researchers to develop a new drug 
delivery system to reduce such adverse effects.
In this study, eight samples of M-MIL-100(Fe), Zn 
I-MIL-100(Fe), Zn II-MIL-100(Fe), Ca I-MIL-100(Fe), 
Ca II-MIL-100(Fe), Mg I-MIL-100(Fe), Mg II-MIL-100(Fe), 
Mn I-MIL-100(Fe), and Mn II-MIL-100(Fe) were synthe-
sized, characterized, and evaluated for their application as a 
drug delivery system to evaluate the loading capacity (LC) 
of M-MIL-100(Fe) for ACF and define M-MIL-100(Fe) as 
a potential drug delivery system for ACF.
Materials and methods
Materials
ACF was purchased from Thermo Fisher Scientific, Waltham, 
MA, USA. All chemicals such as iron chloride hexahydrate 
(FeCl
3
.6H
2
O), benzene-1,3,5-tricarboxylic acid (H
2
BTC, 
C
9
H
6
O
6
), zinc nitrate hexahydrate (Zn (NO
3
)
2
.6H
2
O), calcium 
nitrate tetra hydrate (Ca (NO
3
)
2
.4H
2
O), magnesium chloride 
hexahydrate (MgCl
2
.6H
2
O), and manganese chloride hexa-
hydrate (MnCl
2
.6H
2
O) were supplied by Sigma-Aldrich Co. 
(St Louis, MO, USA) and used without further purification. 
Ethanol (C
2
H
6
O .95%) was purchased from Sigma Aldrich 
and used without further purification. Acetonitrile (C
2
H
3
N 
99.9%) and phosphoric acid (H
3
PO
4
 85%) were supplied 
from Fisher Scientific, Merelbeke, Belgium.
synthesis of M-Mil-100(Fe)
A hydrothermal synthesis procedure was used to prepare the 
M-MIL-100(Fe) samples (Zn I-MIL-100(Fe), Zn II-MIL-
100(Fe), Ca I-MIL-100(Fe), Ca II-MIL-100(Fe), Mg I-MIL-
100(Fe), Mg II-MIL-100(Fe), Mn I-MIL-100(Fe), and 
Mn II-MIL-100(Fe)). Symbols I and II refer to the different 
ratio of a second metal to the iron ion in MIL-100(Fe). 
The MIL-100(Fe) was prepared by mixing 53.38 mmol of 
FeCl
3
.6H
2
O with 23.98 mmol of H
3
BTC (trimesic acid) in 
36 mL of distilled water inside an autoclave (Teflon-lined Figure 1 The chemical structure of aceclofenac.
1+&O &O
2 22 2 +
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autoclave – 4744 acid digestion bomb – 125 mL) and heated 
in an oven at 433 K for 15 hours. Then cooled solution 
was centrifuged and the solid was washed successively in 
hot water (350 mL, 343 K, and 3 hours) and in hot ethanol 
(250 mL, 338 K, and 3 hours). M-MIL-100(Fe) samples 
were synthesized according to the above procedure using the 
amount and type of the second metals as described in Table 1. 
The salt of a second metal was added to the well mixed solu-
tion of parent precursors (FeCL
3
.6H
2
O and H
3
BTC) in H
2
O, 
then continuously mixed for around 30 minutes. Finally, 
the solution was transferred to the autoclave and heated in 
the oven at 433 K for 15 hours; after that, the crystalline 
product was washed as described above for as synthesized 
MIL-100(Fe). The obtained orange-brownish powder was 
dried at 363 K overnight and heated under vacuum at 433 K 
for 12 hours.23
characterization
X-ray powder diffraction (XRPD) was performed using a 
D8 Advance (Bruker AXS, Karlsruhe, Germany), with a 
copper Kα radiation source (40 kV and 40 mA) with a Lynx 
Eye detector. The 2-theta scan range was 5°–20°. NMR 
spectroscopy (Bruker Advance III 400 MHz spectrometer 
(Germany) with BBFO Plus multi-nuclei probe and low and 
high temperature capability). Nuclear magnetic resonance 
(NMR) spectra were referenced to their solvents: deuterium 
oxide (D
2
O, 1H, δ 4.79 ppm). Textural properties of M-MIL-
100(Fe) were characterized by N
2
 adsorption–desorption iso-
therms, which were obtained at 77 K using a micromeritics, 
TriStar-3020 instrument, to determine the specific surface 
area, pore size, and volume. In brief, a 100 mg of the sample 
was first dried at 373 K in an oven and then it was degassed 
by Vac Prep™ 061 at 433 K overnight. Finally, the degassed 
sample was used in the TriStar instrument for analysis after 
getting the net weight of the sample. Fourier transform 
infrared spectra (FTIR) were obtained using a PerkinElmer 
FTIR spectrometer in the range of 650–4,000 cm−1. The 
morphological description was achieved by using a Zeiss 
Neon 40EsB FESEM. Zeta potential was determined by a 
Zeta sizer Nano-ZS (Malvern Instruments, Malvern, UK) 
at 298 K. More specifically, the materials were mixed with 
distilled water and stirred for 1 hour to be suspension system 
at constant temperature (298 K) and then was examined.
loading of acF with M-Mil-100(Fe)
The ACF calibration assay was analyzed by HPLC 
(Shimadzu 20 AC), and the mobile phase was 50 mmol 
phosphate buffer solution at pH 6.8 with acetonitrile 30% 
at a range of ACF concentrations (10, 20, 30, 40, 50, and 
60 µg/mL) in ethanol (95%). The L-max was 274 and the 
flow rate was 1.5 mL/min.
A sample of 40 mg of ACF was dissolved in 10 mL of 
60% ethanol to make solution of 4 mg/mL and analyzed 
by HPLC to determine the amount of ACF before loading. 
A sample of 40 mg of predried M-MIL-100(Fe) at 393 K 
for 6 hours was loaded in the ACF solution in 20 mL glass 
containers. After sealing the container tightly, the mixture 
was stirred (at 150 rpm) for 24 hours at room temperature 
by a magnetic stirrer. The supernatant was collected after 
centrifugation (4,000 rpm, 15 minutes), diluted, and analyzed 
by HPLC to determine the remaining amount of ACF in the 
solution after loading. The remaining solid material in the 
Table 1 Materials and the ratio of metal ions used in the M-Mil-100(Fe) synthesis
M-MOF Metal-based materials Amount used in the synthesis Molar ratio% (M2+/Fe3+)
Zn i-Mil-100(Fe) Fecl3.6h2O 14.43 g (53.3 mmol) 9.9
Zn(nO3)2.6h2O 1.59 g (5.3 mmol)
Zn ii-Mil-100(Fe) Fecl3.6h2O 10.50 g (38.0 mmol) 70
Zn(nO3)2.6h2O 7.94 g (26.6 mmol)
ca i-Mil-100(Fe) Fecl3.6h2O 10.70 g (39.9 mmol) 13.2
ca(nO3)2.4h2O 1.26 g (5.3 mmol)
ca ii-Mil-100(Fe) Fecl3.6h2O 10.69 g (39.5 mmol) 67.3
ca(nO3)2.4h2O 6.29 g (26.6 mmol)
Mg i-Mil-100(Fe) Fecl3.6h2O 14.43 g (53.3 mmol) 11.2
Mgcl2.6h2O 1.22 g (6.0 mmol)
Mg ii-Mil-100(Fe) Fecl3.6h2O 10.45 g (38.6 mmol) 77.7
Mgcl2.6h2O 6.10 g (30.0 mmol)
Mn i-Mil-100(Fe) Fecl3.6h2O 14.43 g (53.3 mmol) 9.4
Mncl2.6h2O 1.22 g (5.0 mmol)
Mn ii-Mil-100(Fe) Fecl3.6h2O 10.45 g (38.6 mmol) 67.3
Mncl2.6h2O 6.10 g (26 mmol)
Abbreviation: M-MOF, multimetal organic framework.
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bottom of the centrifuge tube was dried overnight at 333 K 
in an oven. The loading amount of ACF was calculated by 
subtracting the amount of ACF in the supernatant solution 
from the amount of ACF before loading. The entrapment effi-
ciency (EE), which is the percentage adsorbed at the surface 
of M-MIL-100(Fe), was determined using Equation 1
 
%EE
 ACF (mg)
ACF before loading (mg)
100= ×
Weight-loaded
 
(1)
The LC of M-MOFs was calculated by employing 
Equation 2
 
%LC
 ACF (mg)
Weight of  loaded M MOF (mg)
100=
−
×
Weight-loaded
 
(2)
ACF release profiles
Release profiles used a dissolution tester (Erweka DT6 
unit). A predetermined quantity of loaded M-MIL-100-
(Fe) accurately weighed was submerged into 1,000 mL of 
dissolution medium (50 mmol PBS at either pH 7.4 or 6.8 in 
the dissolution vessel maintained at 37°C ± 1°C with constant 
stirring at 75 rpm). At predetermined time intervals (0.25, 
0.5, 1.5, 4, 5, 6, 12, 24, 30, 48, and 72 hours), an aliquot of 
5 mL was withdrawn and replaced with the same volume 
of fresh dissolution medium. The aliquots were diluted and 
filtered by 0.2 µm syringe filter and analyzed using HPLC. 
All experimental results were triplicate and the standard 
deviation was calculated. A correction of the ACF amount 
in dissolution medium extracted was calculated regarding the 
ACF lost in each aliquot. The released percentage of ACF 
was calculated according to Equation 3
 
Release
Actual ACF released at any time (mg)
Theoretical AC
=
F amount loaded (mg)
100×
 (3)
Results and discussion
Figure 2A–D shows XRPD profiles for loaded and unloaded 
M-MIL-100. Diffraction profiles of M-MIL-100(Fe) and 
Figure 2 XrPD of Mil-100(Fe) and M-Mil-100(Fe) samples (where M is either ca (A), Mg (B), Mn (C), or Zn (D)).
Abbreviation: XrPD, X-ray powder diffraction.
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ACF@M-MIL-100(Fe) samples had similar structures as 
of MIL-100(Fe). However, the crystallinity of ACF@M-
MIL-100 was noticeably decreased when compared with the 
unloaded M-MIL-100(Fe). The peak intensities of loaded 
M-MIL-100(Fe) were reduced while the peak positions in 
the XRPD patterns were similar for the MIL-100(Fe) and the 
corresponding unloaded MIL-100(Fe). The XRPD of differ-
ent structures of M-MIL-100 showed a possible stable frame-
work, which indicates qualitatively ACF loading and the 
integrity of M-MIL-100(Fe) structures after ACF loading.10
Thermal stability of all samples was similar to that of 
main structure of MIL-100(Fe). The structure collapsed 
when the temperature was raised to about 580 K as shown 
in Figure S1. In addition, the morphological descriptions are 
shown in Figure S2. It seems that particle size was similar 
in all samples except in Zn-MIL-100(Fe) samples where the 
particles were enlarged. This is due to adding Zn2+ to the 
MIL100(Fe). It seems that zinc salt might lead to slowing 
down of the nanocrystal nucleation process and growing up 
of the particles size to be larger specially in the presence of 
water as a solvent in the synthesis procedure. This is related to 
the high deliquescent property of zinc nitrate hexahydrate.24,25 
Although the particle size commonly used for drug delivery 
was less than 100 nm, the sizes of particles ranged from 100 
to 250 nm are also preferred in drug delivery system. Hence, it 
can be confirmed that the drug can be delivered to the specific 
organ or tissue in the desired final dose.26 Figure S3 shows 
that functional groups on the surfaces of the pores were main-
tained in M-MIL-100(Fe) samples as in MIL-100(Fe).
The N
2
 adsorption–desorption isotherms for all M-MIL-
100(Fe) samples are shown in Figure 3. The resultant pore 
size, surface area, and pore volume are shown in Table 2. This 
indicates that the content of a second metal in the final product 
was varied and dependent on the type of metal. In addition, 
a lower proportion of the second metal was investigated in 
the final product in compared to the first metal (Fe3+). The 
nonconjoined metal may affect the pore size, pore volume, 
and surface area as it can play a prominent role as a template 
beside the solvent in the synthesis process. Consequently, it 
can be seen that the isotherms are vertical at pressures close 
to 1 atm, indicating that all samples had significantly higher 
pore size and pore volume than MIL-100(Fe).27 Specifically, 
increasing the content of the second metal increased pore 
volume to at least double that of the parent MIL-100(Fe). The 
maximum pore volume displayed with Ca II-MIL-100(Fe), 
Zn I-MIL-100(Fe), and Zn II-MIL-100(Fe) was 1.17, 1, and 
1.04 cm³/g, respectively. In addition, the maximum diameter 
was doubled in MnI-MIL-100(Fe) and Mn II-MIL-100-
(Fe). However, the surface area consequently was reduced 
in M-MIL-100(Fe) (Mn2+, Mg2+, Zn2+) samples below 
MIL-100(Fe), while it declined in Ca I-MIL-100(Fe) and 
increased to 1,848.45 m2/g in Ca II-MIL-100(Fe). This can 
be attributed to that each metal has different coordination 
environment, different ionic radius, different coordination 
geometry, and different affinity to exchange by solvent 
exchange method. When a second metal has different ionic 
radius, different valence number, and different coordina-
tion geometry, it can occupy vacant metal sites in the main 
metal cluster.28–30 Therefore, an increase in the size of ions 
might lead to increase in lattice disorder.31 More specifically, 
activation by solvent exchange process followed by heating 
at 433 K leads to removal of a second metal from the occu-
pied metal site or removal of the whole metal cluster, which 
increases the structural defects, and consequently the pore 
volume and size are enhanced.32,33
Hence the successively incorporating a metal ion followed 
by desolvation can significantly change the textural proper-
ties, which in turn can affect the drug adsorption properties.34 
Significantly, increasing the pore diameter .2 nm was 
observed in all M-MIL-100(Fe) samples; therefore, con-
trolled drug delivery can be enhanced.6
The ACF LC and EE were same values because the 
weights of the M-MIL-100(Fe) and ACF before mixing 
were equal. The LC and EE showed a significant increment 
for all M-MIL-100(Fe) samples in comparison to the MIL-
100(Fe), which is a single metal ion, as shown in Table 2. 
The ACF LC of MIL-100(Fe) was 27%, whereas the LC 
of M-MOFs significantly increased to 37% with Ca I-MIL-
100(Fe) and more than doubled (57% and 59%) when Mn 
II-MIL-100(Fe) and Zn II-MIL-100(Fe) were, respectively, 
employed. These results demonstrated the effects of diversity 
in the pore and volume sizes and surface area of M-MOFs 
as shown in Table 2. The type and percentage of a second 
metal incorporated with an organic linker alongside with the 
Fe ion have a major role in the modification of the function-
alized site in the M-MOF and consequently improving its 
textural characterization.35 The lowest LC of M-MOF was 
37%, which occurred with Ca I-MIL-100-(Fe), and that can 
be related to the lowest pore volume (0.67 cm3/g) and surface 
area (1,078.82 m2/g), while the pore volume and surface 
area of Ca II-MIL-100(Fe) (1.17 cm³/g and 1,848.45 m2/g, 
respectively) have demonstrated increased LC (50%). All 
other M-MIL-100(Fe) type II demonstrated higher loading 
capacities of ACF as compared to the type I. This can be 
related to the increased pore size, pore volume, or surface 
area of M-MIL-100(Fe), which is the effect of the second 
metal within MOF. Increasing the pore size or volume can 
improve the mobility of the drug molecules within the pores by 
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uniformly increasing the diffusion rate in the case of loading 
and release of the drug.36 The highest ACF LC (59%) was with 
Zn II-MIL-100(Fe) owing to the increased pore size and vol-
ume and in addition to the surface area of Zn II-MIL-100(Fe) 
(2.61 nm, 1.04 cm3/g, and 1,590.46 m2/g, respectively). It was 
previously shown that MOFs adsorb drastically different 
amounts of drug as a result of their different pore volumes and 
pore sizes.6,23 No previous study has demonstrated ACF load-
ing with MOF; however, this study shows a significant loading 
of ACF on MOF while the results in previous report showed 
Figure 3 n2 adsorption–desorption isotherms for Mil-100(Fe) (A) and M-Mil-100(Fe) (M is ca (B), Mn (C), Mg (D), or Zn (E)) samples.
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Multi-metal organic frameworks as aceclofenac carriers
that a maximum LC of diclofenac within Zhejiang University 
(ZJU)-101 MOF was accomplished with a rate up to ~50%.37
The NMR analysis showed ACF loading in Figure 4. 
The loading area is represented by the green labeling, which 
is located between 6.3 and 7.5 ppm as shown in Figure 4. 
Presence of aromatic amide in the ACF molecule has 
resonance at 7 theta degree, which shows ACF was proto-
nated and refers to the chemical stability of the adsorbed 
drug in the pores. This spectrum of resonance was same for 
all loaded M-MIL-100(Fe) samples.38,39
Table 2 Textural properties of Mil-100(Fe) and M-Mil-100(Fe) and loading percentages of acF
MIL M/Fe % final 
product
Surface area ± SD 
m²/g
Pore size ± SD 
nm
Pore volume ± SD 
cm³/g
LC% ± SD EE% ± SD
Mil-100(Fe) 0 1,604±5.0 1.29±0.09 0.52±0.02 27±1.9 27±1.9
ca i-Mil-100(Fe) 0.38 1,078±7.9 2.48±0.04 0.67±0.03 37±2.1 37±2.1
ca ii-Mil-100(Fe) 1.75 1,848±6.6 2.53±0.05 1.17±0.03 50±2.2 50±2.2
Mg i-Mil-100(Fe) 0.04 1,508±8.4 2.33±0.02 0.88±0.05 47±1.1 47±1.1
Mg ii-Mil-100(Fe) 0.55 1,384±6.9 2.74±0.02 0.95±0.04 51±3.3 51±3.3
Mn i-Mil-100(Fe) 0.11 1,272±3.0 2.89±0.04 0.92±0.01 45±2.8 45±2.8
Mn ii-Mil-100(Fe) 0.45 1,305±10.0 2.88±0.07 0.94±0.06 57±2.4 57±2.4
Zn i-Mil-100(Fe) 0.07 1,499±7.9 2.67±0.06 1.00±0.07 49±1.7 49±1.7
Zn ii-Mil-100(Fe) 0.17 1,590±9.9 2.61±0.06 1.04±0.04 59±2.5 59±2.5
Abbreviations: ACF, aceclofenac; EE, entrapment efficiency; LC, loading capacity.
Figure 4 nMr of acF and corresponding M-Mil-100(Fe) samples (acF and ca-M-Mil-(Fe) i and ii) (A), (acF and Mg-Mil-100(Fe-) i and ii) (B), (acF and Mn-Mil-
100(Fe) i and ii) (C), and (acF and Zn-Mil-100(Fe) i and ii) (D).
Abbreviations: acF, aceclofenac; nMr, nuclear magnetic resonance.
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Zeta potential measurements were obtained to confirm 
the loading event and stability of nanoparticles of M-MIL-
100(Fe) and ACF@M-MIL-100(Fe) because the surface 
charge of the particles and binding force types between the 
molecules of the drug and the nanoparticles are the most 
important parameters to approve the drug loading efficiency 
and the release rate of drug.40 Zeta potential measurements 
of ACF@M-MIL-100(Fe) were positively increased in com-
parison to the bare M-MIL-100(Fe) as shown in Table 3. This 
result indicated the loading of ACF within M-MIL-100(Fe) 
and the interaction between carboxyl groups of the organic 
linker of M-MIL-100(Fe) samples with hydroxyl group of 
ACF to form ester bond. Therefore, the negativity of the 
carboxylic group in all M- MIL-100(Fe) samples was reduced 
although the changes were small. The binding type and the 
rate of drug loading on the surface of nanoparticles can be 
determined by the surface charge of the MOF and hydro-
phobicity of the drug. By measurement of the zetapotential 
of the MOF before and after loading, one can determine if 
the drug is adsorbed or not due to electrostatic interaction 
between charged block of MOF and oppositely charged drug, 
which has allowed the formation of core–shell, and in this 
way, loading efficiency will be improved.41
The release profiles of ACF were achieved in the simu-
lated GIT and plasma medium of phosphate buffer solutions 
at either pH 6.8 or 7.4. The ACF release profiles are shown 
in Figure 5A–D for all ACF@M-MIL-100(Fe) samples.
The release profiles of ACF in both medium demonstrate 
a slower release-rate profile of ACF@M-MIL-100(Fe) as 
compared to the ACF@MIL-100(Fe) whether at pH 6.8 or 
7.4. There was also a reduction in the release rate in pH 6.8 
medium in comparison with 7.4. The release profiles show a 
difference in the rate of release according to the type of the 
second metal employed in the M-MIL-100(Fe). Although it 
was known that the release rate can be enhanced by increasing 
the pore size,42 the release of ACF from Zn I-MIL-100(Fe) 
and II was slower in comparison to others. The total amounts 
of the ACF released were between 91% with ACF@MIL-
100(Fe) and 75% for ACF@Zn II-MIL-100(Fe) at pH 6.8. 
The slow release profile at pH 6.8 phosphate buffer medium 
can be related to the dissolution rate of ACF at this pH and 
the strength of the interaction of ACF within the pores at the 
surface of M-MOF molecule.43,44 The solubility of ACF and 
consequently its dissolution rate depends on the pKa of ACF 
(4.7) and the pH of the medium therefore the release rate of 
ACF at pH 6.8 medium was slower as comparison to the pH 
7.4 medium. The slow release of ACF@Zn I-MIL-100(Fe) 
and Zn II-MIL-100(Fe) may be related to the competition 
between the phosphate buffer medium and the strength of 
interaction of the ACF within the pores of M-MIL-100-
(Fe).45Also, it may be attributed to the partial degradation 
in the presence of heavier phosphate anions adsorbed on the 
porous framework. Hence, progressive ACF release from 
MIL-Fe(100) solid would be mostly governed by a controlled 
diffusion of the ACF through the slightly amphiphilic pores. 
The rapid release in the first stage of dissolution process may 
be related to the slow collapsing of the MOF structure in the 
phosphate buffer solution with replacement of the carboxy-
late linkers by phosphate groups.46
Conclusion
The second metal was successfully incorporated with base 
metal. A low concentration of the second metal was investi-
gated in the final product although a high concentration was 
used in the synthesis procedure. It seems smaller amounts 
of the second metal (Ca2+, Mn2+, Mg2+, and Zn2+) were incor-
porated in metal center of MIL-100(Fe), and the remaining 
amount worked as a template. Therefore, the textural prop-
erties were improved toward enhancing the pore size and 
pore volume. The drug LC was doubled in comparison to 
the bare MIL-100(Fe). The release-rate profile of ACF was 
promising as a sustained release of the drug. These MOFs 
have a typical nanoparticle size and high stability with high 
loading and very good release rate so that they are promising 
materials for drug delivery systems.
Table 3 Zeta potential values of all M-Mil-100(Fe) and acF@M-
Mil-100(Fe)
MOF Zeta potential (mV) ± SD
Mil-100(Fe) −18.9±0.2
acF@Mil-100(Fe) −12.0±1.0
ca i-Mil-100(Fe) −21.5±0.8
acF@ca i-Mil-100(Fe) −12.2±1.1
ca ii-Mil-100(Fe) −9.97±0.9
acF@ca ii-Mil-100(Fe) −12.6±0.3
Mg i-Mil-100(Fe) −14.7±0.7
acF@Mg i-Mil-100(Fe) −12.3±0.2
Mg ii-Mil-100(Fe) −15.7±0.7
acF@Mg ii-Mil-100(Fe) −10.1±0.9
Mn i-Mil-100(Fe) −18.5±0.8
acF@Mn i-Mil-100(Fe) −11.7±1.0
Mn ii-Mil-100(Fe) −19.4±0.6
acF@Mn ii-Mil-100(Fe) −11.5±0.5
Zn i-Mil-100(Fe) −18.1±0.1
acF@Zn i-Mil-100(Fe) −11.8±0.5
Zn ii-Mil-100(Fe) −18.0±0.5
acF@Zn ii-Mil-100(Fe) −13.2±0.2
Note: ±sD, n=3.
Abbreviations: acF, aceclofenac; MOF, metal organic framework.
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Supplementary materials
Figure S1 TGA profiles of M-MIL-100(Fe) (where M is either Ca, Mg, Mn, or Zn).
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Figure S2 seM images of Mil-100(Fe) and all M-Mils-100(Fe).
Notes: ca i-Mil-100(Fe) (A), ca ii-Mil-100(Fe) (B), Mg i-Mil-100(Fe) (C), Mg ii-Mil-100(Fe) (D), Mn i-Mil-100(Fe) (E), Mn ii-Mil-100(Fe) (F), Zn i-Mil-100(Fe) (G), Zn 
ii-Mil-100(Fe) (H), and Mil-100(Fe) (I).
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Multi-metal organic frameworks as aceclofenac carriers
Figure S3 FTir spectra for M-Mil-100(Fe) (where M is either ca, Mn, Mg, or Zn) samples.
Abbreviation: FTir, Fourier transform infrared.
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